![Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline) Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)](https://pbs.twimg.com/media/E1gxLTUVIAQ3fqE.jpg)
Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)
![PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol](https://congressreport.eu/storage/app/media/ACC%202021/20210607_Steven_Deitelzweig_INT.jpg)
PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
![Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial](https://munin.uit.no/bitstream/handle/10037/24029/article.pdf.jpg?sequence=5&isAllowed=y)
Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
Prevention of cardiac dysfunction during adjuvant breast cancer therapy ( PRADA): a 2 3 2 factorial, randomized, placebo-controll
![PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com](https://cf-images.us-east-1.prod.boltdns.net/v1/jit/5270290550001/a6fca177-b428-4756-be4f-d5c7ee817966/main/1280x720/9m15s61ms/match/image.jpg)
PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/5-Figure1-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/7fb84603-13eb-4ad1-8525-4250c9df1d5f/gr2_lrg.jpg)
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology
![Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ... Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...](https://pbs.twimg.com/media/E3wIBStXoAUKuLP.jpg)
Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...
![PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol](https://congressreport.eu/storage/app/media/ACC%202021/20210525_ACC_Schuyler_Jones_INT.png)
PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
![Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21 Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21](https://pbs.twimg.com/media/E1gu7MIXsAE4ySO.png)
Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21
Prada Receive a Complimentary 4-Pc. trial set with any large spray purchase from the Prada Candy fragrance collection & Reviews - Shop All Brands - Beauty - Macy's
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/4-Table2-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function](https://pbs.twimg.com/media/E1g3DnuWUAExfrg.jpg)
Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function
![Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation](https://www.ahajournals.org/cms/asset/02c15eb9-4540-4421-90b1-846feb79107c/circulationaha.121.054698.fig01.gif)
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation
![Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology](https://www.thelancet.com/cms/asset/53376ae2-bdd3-4d55-810a-dfa3ffdc74f9/gr1.jpg)